Free Trial
→ URGENT: This Altcoin Opportunity Won’t Wait – Act Now (From Crypto Swap Profits) (Ad) Buy CNTA Stock  Free CNTA Stock Alerts

Centessa Pharmaceuticals (CNTA) Financials

Centessa Pharmaceuticals logo
$12.00 -1.57 (-11.60%)
Closing price 05/6/2025 03:59 PM Eastern
Extended Trading
$13.75 +1.75 (+14.62%)
As of 04:26 AM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.
Compare
Annual Income Statements for Centessa Pharmaceuticals

Annual Income Statements for Centessa Pharmaceuticals

This table shows Centessa Pharmaceuticals' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2019 2020 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2022 12/31/2023 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -5.06 -11 -218 -148 -233
Consolidated Net Income / (Loss)		 -5.06 -11 -216 -151 -236
Net Income / (Loss) Continuing Operations		 -5.06 -11 -216 -151 -236
Total Pre-Tax Income 		-5.06 -11 -217 -176 -233
Total Operating Income		 -5.05 -10 -212 -171 -201
Total Gross Profit		 0.00 0.00 0.00 6.85 0.00
Total Revenue		 0.00 0.00 0.00 6.85 0.00
Operating Revenue		 - - 0.00 6.85 0.00
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 5.05 10 210 178 201
Selling, General & Admin Expense		 0.79 1.14 55 54 51
Research & Development Expense		 4.26 9.30 155 124 150
Total Other Income / (Expense), net		 -0.01 -0.22 -4.69 -4.86 -32
Interest Expense		 0.12 0.31 7.28 9.91 44
Interest & Investment Income		 0.01 -0.07 0.24 10 14
Other Income / (Expense), net		 0.11 0.16 2.34 -5.43 -1.69
Income Tax Expense		 0.00 0.00 -0.75 -25 2.84
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 - - 2.19 -5.98 -5.44
Basic Earnings per Share		 $0.00 $0.00 ($2.31) ($1.57) ($2.06)
Weighted Average Basic Shares Outstanding		 0.00 0.00 93.40M 96.18M 114.47M
Diluted Earnings per Share		 $0.00 $0.00 ($2.31) ($1.57) ($2.06)
Weighted Average Diluted Shares Outstanding		 0.00 0.00 93.40M 96.18M 114.47M
Weighted Average Basic & Diluted Shares Outstanding		 - - 94.96M 100.31M 133.18M

Quarterly Income Statements for Centessa Pharmaceuticals

This table shows Centessa Pharmaceuticals' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Income / (Loss) Attributable to Common Shareholders		 -54 -45 -50 -23 -39 -36 -38 -44 -42 -109
Consolidated Net Income / (Loss)		 -54 -43 -51 -25 -39 -37 -38 -44 -43 -111
Net Income / (Loss) Continuing Operations		 -54 -43 -51 -25 -39 -37 -38 -44 -43 -111
Total Pre-Tax Income 		-54 -44 -50 -49 -41 -36 -38 -43 -42 -110
Total Operating Income		 -49 -42 -49 -47 -40 -35 -36 -44 -46 -75
Total Operating Expenses		 49 40 49 47 40 42 36 44 46 75
Selling, General & Admin Expense		 12 14 16 13 12 12 13 11 13 14
Research & Development Expense		 37 28 33 34 28 30 23 33 34 61
Total Other Income / (Expense), net		 -4.99 -2.23 -1.16 -1.92 -1.27 -0.52 -1.48 0.87 4.45 -36
Interest Expense		 1.92 2.20 2.35 2.45 2.54 2.57 2.53 2.53 2.56 37
Interest & Investment Income		 0.08 0.04 2.53 2.06 2.95 2.93 2.59 3.24 3.34 4.85
Other Income / (Expense), net		 -3.14 -0.07 -1.35 -1.53 -1.68 -0.88 -1.54 0.15 3.66 -3.97
Income Tax Expense		 -0.14 -0.66 0.68 -24 -2.83 1.14 0.48 0.71 0.61 1.05
Other Adjustments to Net Income / (Loss) Attributable to Common Shareholders)		 1.11 - -1.80 -0.78 0.33 -3.74 -0.26 -0.03 -0.91 -4.24
Basic Earnings per Share		 ($0.57) ($0.45) ($0.53) ($0.26) ($0.40) ($0.38) ($0.38) ($0.40) ($0.37) ($0.91)
Weighted Average Basic Shares Outstanding		 94.33M 93.40M 94.94M 95.16M 96.65M 96.18M 99.89M 109.49M 116.25M 114.47M
Diluted Earnings per Share		 ($0.57) ($0.45) ($0.53) ($0.26) ($0.40) ($0.38) ($0.38) ($0.40) ($0.37) ($0.91)
Weighted Average Diluted Shares Outstanding		 94.33M 93.40M 94.94M 95.16M 96.65M 96.18M 99.89M 109.49M 116.25M 114.47M
Weighted Average Basic & Diluted Shares Outstanding		 94.60M 94.96M 95.17M 97.40M 97.63M 100.31M 113.04M 113.31M 131.85M 133.18M

Annual Cash Flow Statements for Centessa Pharmaceuticals

This table details how cash moves in and out of Centessa Pharmaceuticals' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2019 2020 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2022 12/31/2023 12/31/2024
Net Change in Cash & Equivalents		 3.70 -9.34 -201 -266 255
Net Cash From Operating Activities		 -5.83 -11 -201 -160 -142
Net Cash From Continuing Operating Activities		 -5.83 -11 -201 -160 -142
Net Income / (Loss) Continuing Operations		 -5.06 -11 -216 -151 -236
Consolidated Net Income / (Loss)		 -5.06 -11 -216 -151 -236
Depreciation Expense		 0.01 0.00 0.13 0.81 0.94
Non-Cash Adjustments To Reconcile Net Income		 0.24 0.52 21 33 68
Changes in Operating Assets and Liabilities, net		 -1.01 -0.49 -5.52 -43 25
Net Cash From Investing Activities		 0.00 0.00 -0.93 -127 31
Net Cash From Continuing Investing Activities		 0.00 0.00 -0.93 -127 31
Purchase of Property, Plant & Equipment		 0.00 0.00 -1.14 -0.17 -0.03
Purchase of Investments		 - - 0.00 -265 -141
Sale and/or Maturity of Investments		 - - 0.00 138 172
Net Cash From Financing Activities		 9.01 1.36 0.46 21 365
Net Cash From Continuing Financing Activities		 9.01 1.36 0.46 21 365
Repayment of Debt		 0.00 0.00 -0.26 0.00 -115
Issuance of Debt		 3.84 1.36 - 0.00 109
Issuance of Common Equity		 0.00 0.00 0.00 21 360
Other Financing Activities, net		 0.00 0.00 0.72 0.31 11
Effect of Exchange Rate Changes		 0.52 -0.08 -0.42 0.62 1.23
Cash Interest Paid		 0.00 0.00 7.28 9.91 10
Cash Income Taxes Paid		 - - 1.30 2.94 0.08

Quarterly Cash Flow Statements for Centessa Pharmaceuticals

This table details how cash moves in and out of Centessa Pharmaceuticals' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Net Change in Cash & Equivalents		 -39 -51 -134 -115 26 -43 -9.81 9.15 268 -12
Net Cash From Operating Activities		 -39 -52 -48 -44 -37 -31 -37 -41 -21 -43
Net Cash From Continuing Operating Activities		 -39 -52 -48 -44 -37 -31 -37 -41 -21 -43
Net Income / (Loss) Continuing Operations		 -54 -43 -51 -25 -39 -37 -38 -44 -43 -111
Consolidated Net Income / (Loss)		 -54 -43 -51 -25 -39 -37 -38 -44 -43 -111
Depreciation Expense		 0.04 0.04 0.09 0.24 0.24 0.25 0.24 0.24 0.24 0.23
Non-Cash Adjustments To Reconcile Net Income		 7.83 8.22 8.99 6.82 8.39 9.22 9.33 8.39 7.73 43
Changes in Operating Assets and Liabilities, net		 6.93 -17 -6.20 -26 -7.37 -3.67 -8.81 -5.39 13 26
Net Cash From Investing Activities		 -0.02 -0.45 -86 -71 49 -18 17 -55 45 25
Net Cash From Continuing Investing Activities		 -0.02 -0.45 -86 -71 49 -18 17 -55 45 25
Sale and/or Maturity of Investments		 - - 0.00 - 86 52 37 65 45 25
Net Cash From Financing Activities		 0.22 0.09 0.00 0.01 15 6.36 10 105 246 2.96
Net Cash From Continuing Financing Activities		 0.22 0.09 0.00 0.01 15 6.36 10 105 246 2.96
Repayment of Debt		 - - - - - - - - -0.97 -112
Issuance of Common Equity		 - - 0.00 - 15 6.24 9.66 107 243 -0.03
Other Financing Activities, net		 0.22 0.09 0.00 0.01 0.18 0.12 0.84 0.80 4.25 5.34
Effect of Exchange Rate Changes		 -0.44 0.72 0.52 0.38 0.22 -0.50 0.22 -0.12 -1.90 3.03
Cash Interest Paid		 1.92 2.20 2.34 2.45 2.54 2.57 2.53 2.52 2.56 2.47
Cash Income Taxes Paid		 - 0.44 0.14 2.57 0.24 -0.00 0.00 0.00 0.01 0.07

Annual Balance Sheets for Centessa Pharmaceuticals

This table presents Centessa Pharmaceuticals' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2020 2021 2022 2023 2024
Period end date 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024
Total Assets		 12 630 444 360 577
Total Current Assets		 11 629 438 315 536
Cash & Equivalents		 7.23 595 394 128 383
Short-Term Investments		 - - - 129 99
Prepaid Expenses		 1.31 18 20 21 10
Other Current Assets		 - - - - 44
Plant, Property, & Equipment, net		 0.00 0.16 1.17 1.04 0.74
Total Noncurrent Assets		 0.55 0.70 1.88 44 40
Noncurrent Deferred & Refundable Income Taxes		 - - - 30 27
Other Noncurrent Operating Assets		 0.55 - - 14 13
Total Liabilities & Shareholders' Equity		 12 630 444 360 577
Total Liabilities		 8.62 138 108 124 175
Total Current Liabilities		 8.62 25 38 39 58
Accounts Payable		 1.03 8.07 14 12 7.14
Accrued Expenses		 1.05 17 25 28 51
Total Noncurrent Liabilities		 0.00 113 70 85 117
Long-Term Debt		 0.00 76 70 76 109
Other Noncurrent Operating Liabilities		 0.00 38 0.00 8.92 8.32
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 -22 492 336 236 402
Total Preferred & Common Equity		 0.00 492 336 236 402
Total Common Equity		 -22 492 336 236 402
Common Stock		 -22 877 940 988 1,386
Retained Earnings		 0.00 -386 -602 -753 -989
Accumulated Other Comprehensive Income / (Loss)		 0.00 0.69 -1.50 1.49 4.21

Quarterly Balance Sheets for Centessa Pharmaceuticals

This table presents Centessa Pharmaceuticals' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q3 2022 Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024
Period end date 9/30/2022 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024
Total Assets		 479 404 393 377 328 399 610
Total Current Assets		 477 384 350 332 284 356 568
Cash & Equivalents		 445 260 145 171 118 127 395
Short-Term Investments		 - 86 158 110 112 167 123
Prepaid Expenses		 12 18 20 23 18 19 16
Current Deferred & Refundable Income Taxes		 20 20 27 28 36 42 34
Plant, Property, & Equipment, net		 0.55 1.22 1.15 1.10 0.95 0.90 0.82
Total Noncurrent Assets		 1.81 18 41 44 43 42 41
Noncurrent Deferred & Refundable Income Taxes		 - - 27 30 29 29 27
Other Noncurrent Operating Assets		 - 18 15 14 14 14 13
Total Liabilities & Shareholders' Equity		 479 404 393 377 328 399 610
Total Liabilities		 106 111 116 118 113 112 111
Total Current Liabilities		 38 30 34 35 27 27 26
Accounts Payable		 11 14 11 11 7.50 5.32 7.44
Accrued Expenses		 27 15 23 24 20 21 19
Total Noncurrent Liabilities		 68 81 82 83 86 85 84
Long-Term Debt		 68 72 73 74 77 77 76
Other Noncurrent Operating Liabilities		 0.04 9.31 9.15 9.02 8.77 8.63 8.47
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 373 293 277 259 215 287 499
Total Preferred & Common Equity		 373 293 277 259 215 287 499
Total Common Equity		 373 293 277 259 215 287 499
Common Stock		 933 946 953 975 1,005 1,120 1,374
Retained Earnings		 -559 -653 -677 -716 -791 -835 -877
Accumulated Other Comprehensive Income / (Loss)		 -1.70 -0.60 0.95 0.78 1.62 1.60 2.10

Annual Metrics and Ratios for Centessa Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Centessa Pharmaceuticals' official financial filings.

Metric 2019 2020 2022 2023 2024
Period end date 12/31/2019 12/31/2020 12/31/2022 12/31/2023 12/31/2024
Growth Metrics		 - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Growth		 0.00% -108.11% 0.00% 16.15% -14.72%
EBIT Growth		 0.00% -107.86% 0.00% 15.82% -14.73%
NOPAT Growth		 0.00% -106.61% 0.00% 19.31% -17.38%
Net Income Growth		 0.00% -110.69% 0.00% 30.12% -56.04%
EPS Growth		 0.00% 0.00% 0.00% 32.03% -31.21%
Operating Cash Flow Growth		 0.00% -82.49% 0.00% 20.05% 11.41%
Free Cash Flow Firm Growth		 0.00% 0.00% 0.00% 0.00% 32.50%
Invested Capital Growth		 0.00% 0.00% 0.00% 699.00% -48.90%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% -100.00%
EBITDA Q/Q Growth		 0.00% 0.00% 0.00% 3.21% -26.69%
EBIT Q/Q Growth		 0.00% 0.00% 0.00% 3.08% -26.52%
NOPAT Q/Q Growth		 0.00% 0.00% 0.00% 3.62% -24.37%
Net Income Q/Q Growth		 0.00% 0.00% 0.00% 4.02% -46.19%
EPS Q/Q Growth		 0.00% 0.00% 0.00% 4.27% -34.64%
Operating Cash Flow Q/Q Growth		 0.00% 0.00% 0.00% 11.34% -9.02%
Free Cash Flow Firm Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 3.27%
Invested Capital Q/Q Growth		 0.00% 0.00% 0.00% 6.43% -49.80%
Profitability Metrics		 - - - - -
Gross Margin		 0.00% 0.00% 0.00% 100.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% -2,566.77% 0.00%
Operating Margin		 0.00% 0.00% 0.00% -2,499.39% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% -2,578.59% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% -2,204.65% 0.00%
Tax Burden Percent		 100.00% 100.00% 99.66% 85.78% 101.22%
Interest Burden Percent		 102.28% 103.68% 103.35% 99.68% 114.88%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% -384.73% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% -372.50% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 331.94% 0.00%
Return on Equity (ROE)		 0.00% -344.19% -52.24% -52.79% -73.93%
Cash Return on Invested Capital (CROIC)		 0.00% -1,175.70% 0.00% -540.24% -271.56%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% -43.93% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% -37.56% 0.00%
Return on Common Equity (ROCE)		 0.00% 2,491.21% -52.24% -52.79% -73.93%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -64.32% -63.95% -58.71%
Net Operating Profit after Tax (NOPAT)		 -3.54 -7.31 -149 -120 -141
NOPAT Margin		 0.00% 0.00% 0.00% -1,749.57% 0.00%
Net Nonoperating Expense Percent (NNEP)		 0.00% -419.38% -20.54% -12.23% -34.30%
Return On Investment Capital (ROIC_SIMPLE)		 - - - -38.44% -27.57%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 784.05% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 1,815.34% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 2,599.39% 0.00%
Earnings before Interest and Taxes (EBIT)		 -4.95 -10 -210 -177 -203
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -4.94 -10 -210 -176 -202
Valuation Ratios		 - - - - -
Price to Book Value (P/BV)		 0.00 0.00 0.86 3.24 4.78
Price to Tangible Book Value (P/TBV)		 0.00 0.00 0.86 3.24 4.78
Price to Revenue (P/Rev)		 0.00 0.00 0.00 111.71 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 216.24 0.00 10.56 54.55
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 85.32 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - -
Debt to Equity		 0.00 1.82 0.21 0.32 0.27
Long-Term Debt to Equity		 0.00 0.00 0.21 0.32 0.27
Financial Leverage		 0.00 -0.52 -0.98 -0.89 -0.87
Leverage Ratio		 0.00 3.78 1.30 1.41 1.47
Compound Leverage Factor		 0.00 3.92 1.34 1.40 1.69
Debt to Total Capital		 0.00% 64.49% 17.19% 24.27% 21.34%
Short-Term Debt to Total Capital		 0.00% 64.49% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 17.19% 24.27% 21.34%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 292.50% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 0.00% -257.00% 82.81% 75.73% 78.66%
Debt to EBITDA		 0.00 -0.55 -0.33 -0.43 -0.54
Net Debt to EBITDA		 0.00 0.16 1.54 1.03 1.85
Long-Term Debt to EBITDA		 0.00 0.00 -0.33 -0.43 -0.54
Debt to NOPAT		 0.00 -0.77 -0.47 -0.63 -0.77
Net Debt to NOPAT		 0.00 0.22 2.18 1.51 2.65
Long-Term Debt to NOPAT		 0.00 0.00 -0.47 -0.63 -0.77
Altman Z-Score		 0.00 18.25 -0.77 0.10 4.00
Noncontrolling Interest Sharing Ratio		 0.00% 823.79% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - -
Current Ratio		 0.00 1.30 11.42 8.00 9.25
Quick Ratio		 0.00 0.84 10.27 6.51 8.31
Cash Flow Metrics		 - - - - -
Free Cash Flow to Firm (FCFF)		 0.00 -8.81 0.00 -168 -114
Operating Cash Flow to CapEx		 0.00% 0.00% -17,638.17% -94,876.92% -417,808.82%
Free Cash Flow to Firm to Interest Expense		 0.00 -28.41 0.00 -17.00 -2.57
Operating Cash Flow to Interest Expense		 -49.36 -34.29 -27.56 -16.19 -3.21
Operating Cash Flow Less CapEx to Interest Expense		 -49.36 -34.29 -27.72 -16.20 -3.22
Efficiency Ratios		 - - - - -
Asset Turnover		 0.00 0.00 0.00 0.02 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 6.21 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - -
Invested Capital		 0.00 1.50 6.93 55 28
Invested Capital Turnover		 0.00 0.00 0.00 0.22 0.00
Increase / (Decrease) in Invested Capital		 0.00 1.50 0.00 48 -27
Enterprise Value (EV)		 0.00 324 -34 585 1,544
Market Capitalization		 300 300 290 766 1,917
Book Value per Share		 $0.00 ($1.49) $3.55 $2.42 $3.05
Tangible Book Value per Share		 $0.00 ($1.49) $3.55 $2.42 $3.05
Total Capital		 0.00 8.73 406 312 510
Total Debt		 0.00 5.63 70 76 109
Total Long-Term Debt		 0.00 0.00 70 76 109
Net Debt		 0.00 -1.60 -324 -181 -373
Capital Expenditures (CapEx)		 0.00 0.00 1.14 0.17 0.03
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 0.00 0.95 5.77 19 -3.77
Debt-free Net Working Capital (DFNWC)		 0.00 8.17 399 276 478
Net Working Capital (NWC)		 0.00 2.55 399 276 478
Net Nonoperating Expense (NNE)		 1.52 3.36 68 31 95
Net Nonoperating Obligations (NNO)		 0.00 -1.60 -329 -181 -373
Total Depreciation and Amortization (D&A)		 0.01 0.00 0.13 0.81 0.94
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 279.56% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 4,023.16% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 4,023.16% 0.00%
Earnings Adjustments		 - - - - -
Adjusted Basic Earnings per Share		 $0.00 $0.00 ($2.31) ($1.57) ($2.06)
Adjusted Weighted Average Basic Shares Outstanding		 0.00 0.00 93.40M 96.18M 114.47M
Adjusted Diluted Earnings per Share		 $0.00 $0.00 ($2.31) ($1.57) ($2.06)
Adjusted Weighted Average Diluted Shares Outstanding		 0.00 0.00 93.40M 96.18M 114.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 0.00 0.00 94.96M 100.31M 133.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -3.54 -7.31 -149 -120 -141
Normalized NOPAT Margin		 0.00% 0.00% 0.00% -1,749.57% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% -2,570.28% 0.00%
Debt Service Ratios		 - - - - -
EBIT to Interest Expense		 -41.93 -33.18 -28.85 -17.84 -4.59
NOPAT to Interest Expense		 -29.98 -23.57 -20.42 -12.10 -3.19
EBIT Less CapEx to Interest Expense		 -41.93 -33.18 -29.00 -17.86 -4.59
NOPAT Less CapEx to Interest Expense		 -29.98 -23.57 -20.57 -12.12 -3.19
Payout Ratios		 - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics and Ratios for Centessa Pharmaceuticals

This table displays calculated financial ratios and metrics derived from Centessa Pharmaceuticals' official financial filings.

Metric Q3 2022 Q4 2022 Q1 2023 Q2 2023 Q3 2023 Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024
Period end date 9/30/2022 12/31/2022 3/31/2023 6/30/2023 9/30/2023 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024
Growth Metrics		 - - - - - - - - - -
Revenue Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Growth		 -29.63% 0.00% 5.40% 23.35% 20.12% 13.99% 25.43% 9.77% -2.06% -118.70%
EBIT Growth		 -29.71% 0.00% 5.28% 23.01% 19.71% 13.48% 25.08% 9.72% -2.04% -117.85%
NOPAT Growth		 -27.96% 0.00% 8.16% 31.27% 17.99% 15.44% 26.16% 6.46% -15.41% -112.01%
Net Income Growth		 -34.17% 0.00% 6.94% 61.51% 28.26% 14.68% 24.98% -76.07% -10.14% -202.22%
EPS Growth		 -26.67% 0.00% 11.67% 62.32% 29.82% 15.56% 28.30% -53.85% 7.50% -139.47%
Operating Cash Flow Growth		 0.00% 0.00% 4.36% 26.41% 4.34% 39.78% 22.06% 7.90% 42.80% -37.84%
Free Cash Flow Firm Growth		 -1,879.79% 0.00% 0.00% 2.59% -45.52% 0.00% -59.19% 30.68% 57.05% 65.63%
Invested Capital Growth		 81.63% 0.00% 88.83% 1,661.18% 1,040.36% 699.00% 231.61% 48.17% 8.34% -48.90%
Revenue Q/Q Growth		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% -100.00% 0.00% 0.00% 0.00%
EBITDA Q/Q Growth		 17.27% 20.14% -20.41% 3.64% 13.79% 14.02% -4.40% -16.59% 2.49% -84.26%
EBIT Q/Q Growth		 17.26% 20.12% -20.52% 3.34% 13.72% 13.92% -4.36% -16.47% 2.48% -83.78%
NOPAT Q/Q Growth		 28.34% 15.14% -17.48% 3.80% 14.48% 12.51% -2.59% -21.86% -5.51% -60.72%
Net Income Q/Q Growth		 16.68% 19.86% -17.47% 50.93% -55.30% 4.69% -3.28% -15.17% 2.85% -161.54%
EPS Q/Q Growth		 17.39% 21.05% -17.78% 50.94% -53.85% 5.00% 0.00% -5.26% 7.50% -145.95%
Operating Cash Flow Q/Q Growth		 34.72% -31.92% 7.23% 7.89% 15.14% 16.96% -20.08% -8.83% 47.29% -100.10%
Free Cash Flow Firm Q/Q Growth		 25.08% 100.00% 0.00% -78.23% -11.92% 14.75% 6.39% 22.39% 30.65% 31.78%
Invested Capital Q/Q Growth		 -310.46% 225.26% 168.74% 148.60% 12.37% 6.43% 11.54% 11.08% -17.84% -49.80%
Profitability Metrics		 - - - - - - - - - -
Gross Margin		 0.00% 0.00% 0.00% 0.00% 0.00% 100.00% 0.00% 0.00% 0.00% 0.00%
EBITDA Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -522.54% 0.00% 0.00% 0.00% 0.00%
Operating Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -513.32% 0.00% 0.00% 0.00% 0.00%
EBIT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -526.13% 0.00% 0.00% 0.00% 0.00%
Profit (Net Income) Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -537.53% 0.00% 0.00% 0.00% 0.00%
Tax Burden Percent		 99.74% 98.49% 101.35% 50.85% 93.19% 103.21% 101.28% 101.64% 101.45% 100.95%
Interest Burden Percent		 103.54% 105.19% 99.63% 100.81% 99.02% 98.99% 99.84% 98.37% 98.17% 140.40%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -79.02% 0.00% 0.00% 0.00% 0.00%
ROIC Less NNEP Spread (ROIC-NNEP)		 0.00% 0.00% 0.00% 0.00% 0.00% -74.23% 0.00% 0.00% 0.00% 0.00%
Return on Net Nonoperating Assets (RNNOA)		 0.00% 0.00% 0.00% 0.00% 0.00% 66.15% 0.00% 0.00% 0.00% 0.00%
Return on Equity (ROE)		 0.00% -52.24% -54.93% -49.57% -49.79% -12.87% 0.00% 0.00% 0.00% -73.93%
Cash Return on Invested Capital (CROIC)		 0.00% 0.00% 0.00% 0.00% 0.00% -540.24% -383.25% -228.15% -216.71% -271.56%
Operating Return on Assets (OROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -8.96% 0.00% 0.00% 0.00% 0.00%
Return on Assets (ROA)		 0.00% 0.00% 0.00% 0.00% 0.00% -9.16% 0.00% 0.00% 0.00% 0.00%
Return on Common Equity (ROCE)		 0.00% -52.24% -54.93% -49.57% -49.79% -12.87% 0.00% 0.00% 0.00% -73.93%
Return on Equity Simple (ROE_SIMPLE)		 0.00% 0.00% -72.43% -62.42% -60.69% 0.00% -64.33% -54.83% -32.31% 0.00%
Net Operating Profit after Tax (NOPAT)		 -34 -29 -34 -33 -28 -25 -25 -31 -32 -52
NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -359.33% 0.00% 0.00% 0.00% 0.00%
Net Nonoperating Expense Percent (NNEP)		 -4.08% -4.27% -4.43% 2.48% -3.59% -4.79% -5.97% -5.81% -3.10% -21.34%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - -7.89% - - - -10.23%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 179.70% 0.00% 0.00% 0.00% 0.00%
R&D to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 433.62% 0.00% 0.00% 0.00% 0.00%
Operating Expenses to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 613.32% 0.00% 0.00% 0.00% 0.00%
Earnings before Interest and Taxes (EBIT)		 -52 -42 -50 -49 -42 -36 -38 -44 -43 -79
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -52 -42 -50 -48 -42 -36 -37 -44 -43 -78
Valuation Ratios		 - - - - - - - - - -
Price to Book Value (P/BV)		 1.02 0.86 1.25 2.13 2.41 3.24 5.25 3.45 3.72 4.78
Price to Tangible Book Value (P/TBV)		 1.02 0.86 1.25 2.13 2.41 3.24 5.25 3.45 3.72 4.78
Price to Revenue (P/Rev)		 0.00 0.00 0.00 0.00 0.00 111.71 164.71 144.27 271.25 0.00
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 0.00 0.00 4.88 7.75 8.03 10.56 15.79 11.22 25.11 54.55
Enterprise Value to Revenue (EV/Rev)		 0.00 0.00 0.00 0.00 0.00 85.32 142.33 112.41 206.65 0.00
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - -
Debt to Equity		 0.18 0.21 0.24 0.27 0.29 0.32 0.36 0.27 0.15 0.27
Long-Term Debt to Equity		 0.18 0.21 0.24 0.27 0.29 0.32 0.36 0.27 0.15 0.27
Financial Leverage		 -1.04 -0.98 -0.96 -0.93 -0.93 -0.89 -0.84 -0.80 -0.86 -0.87
Leverage Ratio		 1.18 1.30 1.27 1.31 1.35 1.41 1.44 1.40 1.30 1.47
Compound Leverage Factor		 1.23 1.36 1.27 1.32 1.34 1.39 1.44 1.38 1.28 2.06
Debt to Total Capital		 15.46% 17.19% 19.62% 20.95% 22.20% 24.27% 26.30% 21.05% 13.17% 21.34%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 15.46% 17.19% 19.62% 20.95% 22.20% 24.27% 26.30% 21.05% 13.17% 21.34%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 84.54% 82.81% 80.38% 79.05% 77.80% 75.73% 73.70% 78.95% 86.83% 78.66%
Debt to EBITDA		 0.00 -0.33 -0.35 -0.38 -0.41 -0.43 -0.47 -0.48 -0.48 -0.54
Net Debt to EBITDA		 0.00 1.54 1.33 1.20 1.14 1.03 0.94 1.38 2.78 1.85
Long-Term Debt to EBITDA		 0.00 -0.33 -0.35 -0.38 -0.41 -0.43 -0.47 -0.48 -0.48 -0.54
Debt to NOPAT		 0.00 -0.47 -0.49 -0.56 -0.59 -0.63 -0.69 -0.70 -0.67 -0.77
Net Debt to NOPAT		 0.00 2.18 1.89 1.76 1.67 1.51 1.38 2.01 3.91 2.65
Long-Term Debt to NOPAT		 0.00 -0.47 -0.49 -0.56 -0.59 -0.63 -0.69 -0.70 -0.67 -0.77
Altman Z-Score		 0.00 0.48 0.36 1.18 1.10 1.39 3.20 3.02 8.92 4.71
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - -
Current Ratio		 12.49 11.42 12.95 10.35 9.51 8.00 10.37 13.29 21.52 9.25
Quick Ratio		 11.65 10.27 11.66 8.96 8.05 6.51 8.39 11.02 19.63 8.31
Cash Flow Metrics		 - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -59 0.00 -43 -77 -86 -73 -68 -53 -37 -25
Operating Cash Flow to CapEx		 -244,300.00% -7,908.59% -54,361.36% -440,620.00% -86,958.14% -110,892.86% 0.00% 0.00% -62,908.82% 0.00%
Free Cash Flow to Firm to Interest Expense		 -30.65 0.00 -18.33 -31.27 -33.74 -28.44 -27.05 -21.03 -14.40 -0.69
Operating Cash Flow to Interest Expense		 -20.34 -23.42 -20.40 -17.98 -14.72 -12.08 -14.74 -16.07 -8.36 -1.17
Operating Cash Flow Less CapEx to Interest Expense		 -20.35 -23.71 -20.44 -17.99 -14.73 -12.09 -14.74 -16.07 -8.38 -1.17
Efficiency Ratios		 - - - - - - - - - -
Asset Turnover		 0.00 0.00 0.00 0.00 0.00 0.02 0.02 0.02 0.01 0.00
Accounts Receivable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.00 0.00 0.00 0.00 0.00 6.21 6.31 6.69 7.13 0.00
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Capital & Investment Metrics		 - - - - - - - - - -
Invested Capital		 -5.54 6.93 19 46 52 55 62 69 56 28
Invested Capital Turnover		 0.00 0.00 0.00 0.00 0.00 0.22 0.17 0.12 0.13 0.00
Increase / (Decrease) in Invested Capital		 25 0.00 8.77 44 58 48 43 22 4.34 -27
Enterprise Value (EV)		 2.56 -34 91 359 418 585 975 770 1,416 1,544
Market Capitalization		 379 290 366 589 625 766 1,129 989 1,859 1,917
Book Value per Share		 $3.95 $3.55 $3.09 $2.91 $2.66 $2.42 $2.15 $2.54 $4.40 $3.05
Tangible Book Value per Share		 $3.95 $3.55 $3.09 $2.91 $2.66 $2.42 $2.15 $2.54 $4.40 $3.05
Total Capital		 441 406 365 350 333 312 292 363 575 510
Total Debt		 68 70 72 73 74 76 77 77 76 109
Total Long-Term Debt		 68 70 72 73 74 76 77 77 76 109
Net Debt		 -377 -324 -275 -230 -207 -181 -153 -218 -443 -373
Capital Expenditures (CapEx)		 0.02 0.65 0.09 0.01 0.04 0.03 0.00 0.00 0.03 0.00
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -6.04 5.77 8.42 13 16 19 27 34 24 -3.77
Debt-free Net Working Capital (DFNWC)		 439 399 355 317 297 276 257 329 542 478
Net Working Capital (NWC)		 439 399 355 317 297 276 257 329 542 478
Net Nonoperating Expense (NNE)		 20 14 17 -8.03 11 12 13 13 10 59
Net Nonoperating Obligations (NNO)		 -378 -329 -275 -230 -207 -181 -153 -218 -443 -373
Total Depreciation and Amortization (D&A)		 0.04 0.04 0.09 0.24 0.24 0.25 0.24 0.24 0.24 0.23
Debt-free, Cash-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 279.56% 392.00% 494.88% 343.05% 0.00%
Debt-free Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 4,023.16% 3,750.78% 4,797.13% 7,908.33% 0.00%
Net Working Capital to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 4,023.16% 3,750.78% 4,797.13% 7,908.33% 0.00%
Earnings Adjustments		 - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.57) ($0.45) ($0.53) ($0.26) ($0.40) ($0.38) ($0.38) ($0.40) ($0.37) ($0.91)
Adjusted Weighted Average Basic Shares Outstanding		 94.33M 93.40M 94.94M 95.16M 96.65M 96.18M 99.89M 109.49M 116.25M 114.47M
Adjusted Diluted Earnings per Share		 ($0.57) ($0.45) ($0.53) ($0.26) ($0.40) ($0.38) ($0.38) ($0.40) ($0.37) ($0.91)
Adjusted Weighted Average Diluted Shares Outstanding		 94.33M 93.40M 94.94M 95.16M 96.65M 96.18M 99.89M 109.49M 116.25M 114.47M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 94.60M 94.96M 95.17M 97.40M 97.63M 100.31M 113.04M 113.31M 131.85M 133.18M
Normalized Net Operating Profit after Tax (NOPAT)		 -34 -29 -34 -33 -28 -25 -25 -31 -32 -52
Normalized NOPAT Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -359.33% 0.00% 0.00% 0.00% 0.00%
Pre Tax Income Margin		 0.00% 0.00% 0.00% 0.00% 0.00% -520.84% 0.00% 0.00% 0.00% 0.00%
Debt Service Ratios		 - - - - - - - - - -
EBIT to Interest Expense		 -27.14 -18.93 -21.42 -19.81 -16.48 -14.03 -14.88 -17.36 -16.72 -2.15
NOPAT to Interest Expense		 -17.86 -13.23 -14.59 -13.43 -11.08 -9.58 -9.99 -12.19 -12.70 -1.43
EBIT Less CapEx to Interest Expense		 -27.15 -19.22 -21.45 -19.82 -16.50 -14.04 -14.88 -17.36 -16.73 -2.15
NOPAT Less CapEx to Interest Expense		 -17.86 -13.52 -14.63 -13.44 -11.09 -9.59 -9.99 -12.19 -12.72 -1.43
Payout Ratios		 - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Frequently Asked Questions About Centessa Pharmaceuticals' Financials

When does Centessa Pharmaceuticals's financial year end?

According to the most recent income statement we have on file, Centessa Pharmaceuticals' fiscal year ends in December. Their fiscal year 2024 ended on December 31, 2024.

How has Centessa Pharmaceuticals' net income changed over the last 4 years?

Centessa Pharmaceuticals' net income appears to be on an upward trend, with a most recent value of -$235.76 million in 2024, rising from -$5.06 million in 2019. The previous period was -$151.09 million in 2023. Check out Centessa Pharmaceuticals' forecast to explore projected trends and price targets.

What is Centessa Pharmaceuticals's operating income?
Centessa Pharmaceuticals's total operating income in 2024 was -$201.06 million, based on the following breakdown:
  • Total Gross Profit: $0.00
  • Total Operating Expenses: $201.06 million
How has Centessa Pharmaceuticals revenue changed over the last 4 years?

Over the last 4 years, Centessa Pharmaceuticals' total revenue changed from $0.00 in 2019 to $0.00 in 2024, a change of 0.0%.

How much debt does Centessa Pharmaceuticals have?

Centessa Pharmaceuticals' total liabilities were at $175.25 million at the end of 2024, a 41.3% increase from 2023, and a 1,933.3% increase since 2020.

How much cash does Centessa Pharmaceuticals have?

In the past 4 years, Centessa Pharmaceuticals' cash and equivalents has ranged from $7.23 million in 2020 to $595.08 million in 2021, and is currently $383.22 million as of their latest financial filing in 2024.

How has Centessa Pharmaceuticals' book value per share changed over the last 4 years?

Over the last 4 years, Centessa Pharmaceuticals' book value per share changed from 0.00 in 2019 to 3.05 in 2024, a change of 304.6%.


Related Companies

This page (NASDAQ:CNTA) was last updated on 5/7/2025 by MarketBeat.com Staff
From Our Partners
Elon’s Terrifying Warning Forces Trump To Take Action
Elon Musk has avoided two major financial crises before. He pulled Tesla and SpaceX back from the brink of col...
American Hartford Gold | Sponsored
Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...
Porter & Company | Sponsored
URGENT: Someone's Moving Gold Out of London...
People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...
Golden Portfolio | Sponsored
Gold Hits New Highs as Global Markets Spiral
When Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...
Premier Gold Co | Sponsored
Trump’s Bitcoin Reserve is No Accident…
Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...
Crypto 101 Media | Sponsored
3..2..1.. AI 2.0 ignition (don’t sleep on this)
I just put together an urgent new presentation that you need to see right away. In short: I believe we are...
Timothy Sykes | Sponsored
Virtually Limitless Energy?
A radical energy breakthrough could change everything. Scientists at MIT and a stealth startup may have discov...
Stansberry Research | Sponsored
Elon just did WHAT!?
As you may recall, Biden and the Fed were working on a central bank digital currency, or CBDC. Had they got...
Brownstone Research | Sponsored